Document is current
Any future updates will be listed below
-
Authors
Nickl-Jockschat, T.
Steiner, J.
Hirjak, D.
Hasan, A.
-
Funding
Funding for this research was provided by:
Otto-von-Guericke-Universität Magdeburg
- License Information
-
More Information
Article History
Accepted: 25 June 2025
First Online: 4 September 2025
Declarations
:
: T. Nickl-Jockschat has received lecture honoraria from Janssen-Cilag and has been invited to conferences by Boehringer-Ingelheim. J. Steiner has received lecture honoraria from Janssen-Cilag and Boehringer-Ingelheim; invitations to conferences or other activities were declined. D. Hirjak has received honoraria from Rovi and Teva, lecture fees from the DGPPN, and editorial honoraria from Elsevier and Thieme Verlag. A. Hasan has received lecture honoraria from AbbVie, Advanz, Janssen, Otsuka, Rovi, Recordati, and Lundbeck. He has also served on advisory boards for Boehringer-Ingelheim, Teva, AbbVie, Janssen, Otsuka, Rovi, Recordati, and Lundbeck; invitations to conferences or other activities were declined. A. Hasan is also the lead editor of the AWMF S3 Guideline on Schizophrenia.
: For this article no studies with human participants or animals were performed by any of the authors. All studies mentioned were in accordance with the ethical standards indicated in each case.
: The supplement containing this article is not sponsored by industry.
